News & Updates

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

28 Jan 2021 by

A combination therapy of umbralisib + ublituximab (U2) significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL) compared with obinutuzumab + chlorambucil (O+Chl), according to the UNITY-CLL* study presented at ASH 2020.

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

28 Jan 2021

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

27 Jan 2021

Cisplatin-ineligible patients with metastatic urothelial carcinoma treated with PD-1/L1 inhibitor followed by carboplatin-containing chemotherapy show similar overall survival (OS) with those treated with the reverse sequence, a study has found.

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

27 Jan 2021

Malaysia proudly home to largest genetic database of Asian breast cancers

27 Jan 2021 by

Cancer Research Malaysia (CRM), in collaboration with University of Cambridge and Subang Jaya Medical Centre (SJMC) has assembled the largest genetic and genomic database of Asian breast cancers.

Malaysia proudly home to largest genetic database of Asian breast cancers

27 Jan 2021

Gastric acid suppression plus sorafenib may lower survival in advanced HCC

26 Jan 2021

Progression-free (PFS) and overall survival (OS) are significantly lower in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib and concomitant gastric acid suppression therapy, a recent study has found.

Gastric acid suppression plus sorafenib may lower survival in advanced HCC

26 Jan 2021

Tobacco use significantly associated with bladder cancer incidence and mortality

26 Jan 2021 by

An international team of researchers led by CUHK found a significant association between tobacco use and bladder cancer incidence and mortality globally.

Tobacco use significantly associated with bladder cancer incidence and mortality

26 Jan 2021

Magnetic seed markers safe and effective for nonpalpable breast lesion localization in Chinese women

26 Jan 2021 by

A retrospective review of a pilot study in Chinese women who underwent magnetic seed marker–guided breast lesion excision reports >90 percent success rate and no complications.

Magnetic seed markers safe and effective for nonpalpable breast lesion localization in Chinese women

26 Jan 2021

High morbidity and mortality among COVID-19 patients with haematologic malignancies

26 Jan 2021 by

Patients with coronavirus disease 2019 (COVID-19) who have haematologic malignancies have a 28 percent mortality rate, according to data collected from 250 patients by the ASH Research Collaborative COVID-19 presented at the 62^nd American Society of Hematology Annual Meeting and Exposition (ASH 2020).

High morbidity and mortality among COVID-19 patients with haematologic malignancies

26 Jan 2021

ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer

26 Jan 2021 by

Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïve RET-mutated (RETmut) medullary thyroid cancer (MTC) patients.

ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer

26 Jan 2021

CUHK review informs international collaborative consensus statement on en bloc resection of bladder tumour

26 Jan 2021 by

Researchers from The Chinese University of Hong Kong carried out two systematic reviews of 10 randomized clinical trials (RCTs), which compared the effectiveness of en bloc resection of bladder tumour (ERBT) as an oncologically noninferior alternative to transurethral resection of bladder tumour (TURBT). In-depth RCT meta-analyses were followed by a two-round Delphi survey of >100 respondents with ERBT experience and a 16-member expert panel meeting, which culminated in the publication of a consensus statement addressing every aspect of ERBT.

CUHK review informs international collaborative consensus statement on en bloc resection of bladder tumour

26 Jan 2021

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

25 Jan 2021 by

The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

25 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

UNITY-CLL: Umbralisib + ublituximab prolongs PFS in CLL

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

Which sequence is most efficacious for PD-1/L1 inhibitors, carboplatin-based chemotherapy?

Malaysia proudly home to largest genetic database of Asian breast cancers

Malaysia proudly home to largest genetic database of Asian breast cancers

Gastric acid suppression plus sorafenib may lower survival in advanced HCC

Gastric acid suppression plus sorafenib may lower survival in advanced HCC

Tobacco use significantly associated with bladder cancer incidence and mortality

Tobacco use significantly associated with bladder cancer incidence and mortality

Magnetic seed markers safe and effective for nonpalpable breast lesion localization in Chinese women

Magnetic seed markers safe and effective for nonpalpable breast lesion localization in Chinese women

High morbidity and mortality among COVID-19 patients with haematologic malignancies

High morbidity and mortality among COVID-19 patients with haematologic malignancies

ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer

ARROW: Pralsetinib achieves potent and durable responses in RETmut medullary thyroid cancer

CUHK review informs international collaborative consensus statement on en bloc resection of bladder tumour

CUHK review informs international collaborative consensus statement on en bloc resection of bladder tumour

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer